Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Mixed dyslipidemia – pipeline review, h1 2012


Published on

Aarkstore Enterprise-Mixed Dyslipidemia – Pipeline Review, H1 2012 || Market Research latest report

  • Be the first to comment

  • Be the first to like this

Mixed dyslipidemia – pipeline review, h1 2012

  1. 1. announces, The Latest market research report is available inits vast collection:Mixed Dyslipidemia – Pipeline Review, H1 2012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s, Mixed Dyslipidemia - Pipeline Review, H1 2012, provides anoverview of the Mixed Dyslipidemia therapeutic pipeline. This report providesinformation on the therapeutic development for Mixed Dyslipidemia, complete withlatest updates, and special features on late-stage and discontinued projects. It alsoreviews key players involved in the therapeutic development for MixedDyslipidemia. Mixed Dyslipidemia - Pipeline Review, H1 2012 is built using data andinformation sourced from Global Markets Direct’s proprietary databases,Company/University websites, SEC filings, investor presentations and featuredpress releases from company/university sites and industry-specific third partysources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Mixed Dyslipidemia.- A review of the Mixed Dyslipidemia products under development by companiesand universities/research institutes based on information derived from companyand industry-specific sources.
  2. 2. - Coverage of products based on various stages of development ranging fromdiscovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.Table of contents:List of Tables 4List of Figures 4Introduction 5Global Markets Direct Report Coverage 5Mixed Dyslipidemia Overview 6Therapeutics Development 7An Overview of Pipeline Products for Mixed Dyslipidemia 7Mixed Dyslipidemia Therapeutics under Development by Companies 9Late Stage Products 10Comparative Analysis 10Early Clinical Stage Products 11Comparative Analysis 11Pre-Clinical Stage Products 12Comparative Analysis 12Mixed Dyslipidemia Therapeutics – Products under Development by Companies 13Companies Involved in Mixed Dyslipidemia Therapeutics Development 14Merck & Co., Inc. 14Pronova BioPharma ASA 15Intas Pharmaceuticals Ltd. 16Ache Laboratorios Farmaceuticos S/A 17Mixed Dyslipidemia – Therapeutics Assessment 18Assessment by Monotherapy Products 18Assessment by Combination Products 19Assessment by Route of Administration 20Assessment by Molecule Type 22Drug Profiles 24MK-0524A - Drug Profile 24Product Description 24Mechanism of Action 24
  3. 3. R&D Progress 24IN-SUPR-001 - Drug Profile 26Product Description 26Mechanism of Action 26R&D Progress 26NanoActive Rosuvastatin - Drug Profile 27List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H1 2012 Review, H12012&PubId=&pagenum=1Bacteremia – Pipeline Review, H1 2012Staphylococcus Aureus Infections – Pipeline Review, H1 2012Warts – Pipeline Review, H1 2012Mixed Dyslipidemia – Pipeline Review, H1 2012Gastroenteritis – Pipeline Review, H1 2012Hypereosinophilic Syndrome – Pipeline Review, H1 2012
  4. 4. Familial Adenomatous Polyposis Coli – Pipeline Review, H1 2012Tinnitus – Pipeline Review, H1 2012Shock – Pipeline Review, H1 2012Influenza B Infections – Pipeline Review, H1 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcare andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: